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Transplantation Data
Treatment Group CB dose (x 10*6) T-cell dose (x 10*6) GVHD (score 1-10) Engraftment Survival
1 (CB alone) 0.5 - 10 - 1/37 (3) 1/37 (2.7%) 36/37 (97%)
2 (CB1 T) 1.0 – 3.0 3.0 3/8 (6) 3/8 (38%) 4/8 (50%)
3a (CB1 S59 T) 0.5 – 3.0 1.0 – 3.0 0/16 1/16 (6.3%) 16/16 (100%)
3b (CB1 S59 T) 3.0 9.0 1/8 (3) 6/8 (75%) 8/8 (100%)
3c (CB1 S59 T) 6.0 3.0 0/6 3/6 (50%) 6/6 (100%)
T- T lymphocyte, CB- Cord blood
Oral Presentations S161GVHD were minimal. Donor MHC high/c-kit+/lineage-/CD34-
stem cells were noted in the recipient bone marrow compartment
(Group3b). Although lineage specific markers for lymphoid,
myeloid and erythroid series were expressed in the host bone mar-
row and spleen mice by day 30, full hematological recovery was
delayed until 50-60 days after CBT. In-vitro mixed lymphocyte re-
action with S-59 treated T cells demonstrated a 6 fold increase in
Foxp3 + CD4 +CD25+ regulatory T cells after 72 hours of co-cul-
ture compared to control (p5 0.0002).
Conclusions: These results show improved cord blood engr-
aftment kinetics across a disparate H2 haplotype by adding pso-
ralen-treated donor T lymphocytes. Co-transplantation of
psoralen treated lymphocytes with CB cells facilitated durable en-
graftment of donor MHC high/c-kit+ cells in the marrow and
splenic compartments with complete but delayed hematopoietic
recovery. The low GVHD risk and excellent long-term survival
observed in this murine model suggests the potential for clinical
application.18
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Background: Various prospective trials which employed genetic al-
location of post-remission treatment have been performed to assess
the role of allogeneic hematopoietic cell transplantation (allo-HCT)
in the treatment of AML in CR1. However, it has been difficult to
clearly demonstrate the clinical benefit of allo-HCT in patients
with AML in CR1. A decision analysis with the Markov process is
a flexible and convenient analytical method that tracks the clinical
events that occur after a certain decision with different probabilities
over time. To address the role of allo-HCT for AML in CR1, we
performed a Markov decision analysis using newly collected clinical
data from 2029 patients.
Methods: Probabilities and other outcome data were derived from
a database of adult AML patients that was constructed from case re-
port files collected for this study.We included patients who were di-
agnosed with AML other than M3 between 1999 and 2006, aged 16
to 70 years, and who had achieved CR1 after 1 or 2 courses of induc-
tion chemotherapy. Using the software package TreeAge Pro, we
constructed a Markov decision model that compared 2 strategies:
allo-HCT in CR1 (HCT group) and no allo-HCT in CR1 (CTx
group). Quality-of-life (QOL) adjustments were made by incorpo-
rating time trade-off utilities that were derived from a questionnaire
to 13 physicians. The cycle length between state transitions was set at
3 months.
Results: A total of 2029 patients were eligible for this analysis. The
median age was 50 years, and the median follow-up of the surviving
patients was 4.1 years. The proportions of patients with favorable,
intermediate, unfavorable and unknown cytogenetic risk by
SWOG criteria were 20%, 54%, 17% and 9%, respectively. Thera-pies performed at CR1 were allo-HCT in 494 patients (24%) and
chemotherapy in 1535 patients (76%). Life expectancy of the
HCT group was longer than that of the CTx group (4.96 vs. 4.44
years, Table1). However, quality-adjusted life expectancy of the
HCT group was comparable to that of the CTx group (4.06 vs.
3.98 years). In patients with intermediate-risk or unfavorable-risk
AML, allo-HCT in CR1 was associated with a longer life expectancy
compared to the CTx group, and adjustment for QOL did not
change the preferred decision.
Conclusion: The results indicated that patients with intermediate-
or unfavorable-risk AML have a longer life expectancy and quality-
adjusted life expectancy with a decision of allo-HCT in CR1.
Life Expectancy and QOL-Adjusted Life Expectancy (years)
Allo-HCT in CR1 No Allo-HCT in CR1Life
Expectancy QOL-AdjustedLife
Expectancy QOL-AdjustedTotal 5.09 4.18 4.44 3.97
SWOG
Favorable 5.00 4.13 5.41 4.86
Intermediate 5.38 4.43 4.46 4.01
Unfavorable 4.66 3.74 3.27 2.9119
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The optimal approach for GVHD prophylaxis remains uncertain
and novel strategies are needed. It has been argued that, due to sub-
jectivity in scoring clinical signs of GVHD, additional, more objec-
tive endpoints should be used. One ofmore persuasive ones is the use
of SSI beyond the originally planned prophylaxis.We retrospectively
compared the incidence of GVHD and the use of SSI in 139 consec-
utive patients with advanced hematologic malignancies treated on
a phase II trial using HiCy as a single agent prophylaxis of GVHD
following HLA-matched related and unrelated BMT. We hypothe-
sized that use of this prophylactic strategy will promote tolerance
induction, improve the control of GVHD, and thereby decrease
the overall use of SSI. Patients, median age 49 (21-66), of whom
53% were not in remission at the time of transplant, received
HLA-matched related (n5 79) or unrelated (n5 60) BM after mye-
loablative BuCy conditioning. HiCy (50 mg/kg/day) was given on
days +3, and +4 as only planned GVHD prophylaxis. Patients with
acute grade II-IV GVHD were treated with methylprednisolone
1-2.5 mg/kg/day IV as a first line therapy, and those with visceral
GVHD also received calcineurin inhibitors (CNI) or other non-
CNI immunosuppressants. In the competing risk model (death and
graft failure as competing risks), the incidence of acute grade II-IV
and III-IVGVHDby day 200 was 50% and 16%, respectively. Thir-
teen percent of patients who developed acute grade II-IV GVHD
were not treated 15%were treated with steroids alone, 63%with ste-
roids plus a CNI and 9% with steroids plus non CNI-based agents.
Overall cumulative incidence of SSI use was 45%. Median time to
initiation of SSI was 42 (19-142) days and the median duration of
S162 Oral PresentationsSSI use was 152 (13-981) days. At 6months and 1 year, 63% and 83%
of patients were off all immunosuppressive therapy, respectively.
With a median follow-up of 26 months, cumulative incidence of
chronic GVHD was 10%. Only 3 patients have died with refractory
GVHD. These results extend our previous observations that post-
transplantation Cy is effective single agent strategy for prophylaxis
of acute GVHD with both a low rate of grade III-IV and more
than half of the patients never requiring additional SSI. The limited
use of SSI may be responsible for low infectious rate and excellent
immune reconstitution seen in these patients. This approach also
provides novel platform to facilitate the use of post-transplant immu-
notherapy aimed at reducing relapse.20
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Objective: To evaluate the impact of HLA matching and differ-
ence in matching degree among transplants from unrelated donors
(UD) on different outcomes in chronic lymphocytic leukemia
(CLL).
Materials & Methods: We have analyzed 370 CLL patients who
underwent an allogeneic HSCT reported to the EBMT registry.
There were 280 males (75%) and 90 females with a median age of
53 years (24-69). At transplant, 294 among 317 evaluated patients
had a good performance status (PS) (93%), 43 patients were in CR
(12%), 160 in PR (46%), 44 in SD (13%) and 103 in PD (29%)
among 349 evaluated patients. Two hundred and sixty six patients re-
ceived a reduced intensity conditioning regimen (RIC) and 103
a standard (Std) conditioning; 313 patients received PBSC, 56 BM
and 2 cord blood cells from 198HLA siblings, and 172 unrelated do-
nors (UD).According to the registry, there were 198 HLA siblings,
135matchedUD (MUD) and 37mismatchedUD (MMUD).We fo-
cused on UD and re-analyzed all HLA typings for patients and do-
nors, after classification we found: 31 well matched (10/10, 8/8) in
high resolution), 30 matched in low resolution and 111 mismatched
in high resolution.
We found a high significant difference in term of OS between the
siblings, well & partially matched groups versus low & MMUD
groups (p5 0.002) (figure2). [OS at 3 & 5 years: Siblings: 68.3%
(61.8-75.5) and 57.2% (49.8-65.6); well matched: 60.8% (43.1-85.8)
from 3 to 5 years, low resolution &MMUD: 50.5% (43.1-60.1) and
39.6% (29.5-50.2) respectively]. We observed also a high significant
difference in term of transplant relatedmortality (TRM) between the
same groups (p5 0.0024) (figure4). The multivariate analysis using
Cox model studying age, pre-transplant status, gender, PS, cells
source, ABO compatibility, conditioning and different HLA groups,
showed a significant impact of 3 factors onOS: age [HR5 1.04 (1.02-
1.6) p5 0.001], PS [HR5 2.75 (1.5-5.1) p5 0.001] and HLA
MMUD+Low resolution group [HR5 1.43 (1.01-2.01) p5 0.04].
The same factors were also highly significant in multivariate analysis
in term of TRM (age: HR5 1.04 (1.001-1.07) p5 0.0033; PS:
HR5 2.47 (1.1-5.4) p5 0.009 and HLA MMUD group: HR5 1.8
(1.07-3.37) p5 0.004.21
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This retrospective report assessed the outcome of 629 patients
aged$60 years and who received RIC allo-SCT, with a special em-
phasis on the comparison of the outcome of patients aged 60-65 and
patients aged .65 y.
The median age for the whole cohort was 62 (range, 60-71) y. 378
patients (55%) had a myeloid malignancy, while 240 (38%) had lym-
phoid malignancies, and 11 (2%) had other diseases. 386 patients
(61%) received allo-SCT from an HLA-matched related donor,
while 199 patients (32%) received the graft from a MUD, and 44
(7%) frommismatched donors. The conditioning regimen consisted
of Fludarabine and Busulfan in 280 cases (44.5%), Fludarabine and
low dose TBI in 150 cases (24%). The remaining 199 patients
(32%) received other so-called RIC regimens.
With a median follow-up of 9 (range, 1-90) m., grade II-IV and
grade III-IV acute GVHD occurred in 29% (n5 182) and 12%
(n5 76) of patients, respectively. Chronic GVHD was observed
in 145 patients (23%; limited: n5 67; extensive: n5 72; unknown
stage: n5 6). 180 patients died of transplant-related causes
(TRM: 29%). The estimates of overall survival (OS) at 1 and 2
years were 57% (95%CI, 53-62%) and 47% (95%CI, 42-52%),
respectively.
In order to assess the applicability of RIC allo-SCT to the older
age group, we compared the outcome of patients aged from 60 to
65 y. (n5 516) and those aged .65 y. (n5 113). Except for age, in
univariate analysis, these 2 groups were not statistically different in
terms of demographic, disease or transplant characteristics. The
incidences of grade II-IV and grade III-IV acute GVHD were com-
parable between both groups (29% vs. 30%, p5NS; and 12% vs.
12%; p5NS). The TRM incidence was 29% in the younger group
vs. 27% in the older group (p5NS). The estimates of OS at one and
2 years were 58% (95%CI, 53-62%) and 47% (95%CI, 42-52%) in
the younger age group and 55% (95%CI, 44-65%) and 48%
(95%CI, 37-60%) in the older age group (p5NS). In a Cox multi-
variate analysis accounting for all relevant factors, age.65 y. was not
found to be a statistically significant factor associated with worsened
survival.
In all, this data support the use of RIC-allo-SCT in patients.60 y.
Outcome of patients aged.65 y. appears to be comparable to that of
patients aged 60-65 y. Physiologic aging is likely more important
than chronologic aging. With the refinement of comorbidities scor-
ing systems, age per se (at least up to 70 y.) should not be a contrain-
dication to perform RIC allo-SCT.22
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While non-myeloablative conditioning significantly reduces mor-
bidity and mortality after allogeneic hematopoietic cell transplanta-
tion (HCT), the risk of allograft rejection is increased. Persistent
host cells mediate host-vs-graft alloreactivity or occupy niches in
the hematopoietic microenvironment. Here we studied engraftment
and hematopoietic reconstitution in BALB.K mice given non-mye-
loablative radiation and purified hematopoietic stem cells (HSC:
cKIT +Thy1.1loSca1 + Lin-) +/- T cells (TC) from AKR/J donors,
a MHC-identical (H-2 K) model with high barriers to engraftment.
Recipients of pure HSC regularly achieved stable mixed chimerism.
However, if grafts contained CD4 TC (but not CD8 TC) donor
lymphopoiesis was completely abolished in 80% of hosts, even
long-term. This suppression was associated with bone marrow
(BM) lymphopenia (\5% vs .40% after HSC alone), and hypocel-
lularity (median 3.8 vs 13.3 x10^6 cells/2 legs; p5 0.0003) at 2 weeks
post-HCT. B cell reconstitution was the most severely affected (6%
vs 75% of lymphocytes). At this early time point there was expansion
of donor and host CD4 TC, each comprising 6% of BM cells (vs
